Details of the Drug Combination

General Information of Drug Combination (ID: DC9MTEG)

Drug Combination Name
Tegobuvir GS-9256
Indication
Disease Entry Status REF
Discovery agent Investigative [1]
Component Drugs Tegobuvir   DM6YI5T GS-9256   DMCZH5B
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tegobuvir
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 2 [2]
Tegobuvir Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) TTMVBWH POLG_HCV1 Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of GS-9256
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 2 [2]
GS-9256 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Protease (HIV PR) TT5FNQT POL_HV1B1 Inhibitor [2]
------------------------------------------------------------------------------------

References

1 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2 Clinical pipeline report, company report or official report of Gilead (2011).